ITeos Therapeutics

iTeos Therapeutics is focused on the validation and development of "immunomodulatory" molecules with the potential to act in synergy with other cancer therapies to restore immune activity against tumours. The company is interested in three enzymes involved in immunosuppression:

  • an immunosuppressive enzyme expressed by the tumour's stromal cells. An inhibitor of this enzyme is known and its effects on humans have already been studied for other applications. iTeos hopes to begin clinical trials with this molecule by 2014;

  • indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), for which iTeos will soon be launching a high-speed screening system for identifying inhibitory molecules. The company hopes to develop an immunomodulator from these two enzymes by 2017.

  • iTeos is a spin-off of the Brussels' Ludwig Institute for Cancer Research (LICR) and the Université Catholique de Louvain.



Contact : Michel Detheux

Rue Auguste Piccard 48,
B-6041 Gosselies.
michel.detheux[at]iteostherapeutics.com
info[a]iteostherapeutics.com

Website